part of it would continue in FY22E/23E too. Its recent performance in 4Q was below our estimates due to 1) unfavorable product mix with lack of COVID portfolio growth in India, 2) anti-infective portfolio continued to setback lower volume in India, 3) stagnant US sales at around US$140m over four quarters,...